KFDA agonizes over extended duration of new drug approvals

Published: 2004-02-12 07:00:00

Updated: 2004-02-12 07:00:00

The Korea Food and Drug Administration has worried the extended period of screening the approval of new drugs due to shortage of manpower, as all of drug license business was incorporated into the National Toxicity Research Institute during the latter half of last year and furthermore, the review...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK